May 6, 2020 / 12:18 PM / 25 days ago

BRIEF-Alnylam Pharmaceuticals Reports Q1 2020 Financial Results

May 6 (Reuters) - Alnylam Pharmaceuticals Inc:

* ALNYLAM PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PERIOD ACTIVITY

* SEES FY 2020 REVENUE UP 5 PERCENT

* LOWERS 2020 GUIDANCE RANGE FOR ONPATTRO REVENUE FROM $285-$315 MILLION TO $270-$300 MILLION DUE TO COVID-19 PANDEMIC

* ALNYLAM PHARMACEUTICALS - CASH, CASH EQUIVALENTS, MARKETABLE DEBT AND EQUITY SECURITIES, AND RESTRICTED INVESTMENTS WERE $1.37 BILLION AT END OF Q1 2020

* SEES FY 2020 GAAP RESEARCH AND DEVELOPMENT AND SG&A EXPENSES OF $1,155 MILLION - $1,250 MILLION

* QTRLY LOSS PER SHARE OF $1.62

* Q1 EARNINGS PER SHARE VIEW $-1.89 — REFINITIV IBES DATA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below